See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/49968162

ChemInform Abstract: Stereoselective Synthesis of Complex Polycyclic Aziridines (XI): Use of the Broensted Acid-Catalyzed Aza-Darzens Reaction to Prepare an Orthogonally Protected...

ARTICI F in	CHEMICAL	COMMUNICATIONS	<ul> <li>FFBRUARY 2011</li> </ul>

Impact Factor: 6.83  $\cdot$  DOI: 10.1039/c0cc05734g  $\cdot$  Source: PubMed

CITATIONS READS

4

### **5 AUTHORS**, INCLUDING:



John C Huffman
Indiana University Bloomington
1,226 PUBLICATIONS 27,300 CITATIONS

SEE PROFILE



49

Jeffrey N. Johnston
Vanderbilt University

111 PUBLICATIONS 2,428 CITATIONS

SEE PROFILE

Published in final edited form as:

Chem Commun (Camb). 2011 April 7; 47(13): 3975–3977. doi:10.1039/c0c05734g.

# Stereoselective Synthesis of Complex Polycyclic Aziridines: Use of the Brønsted Acid-Catalyzed aza-Darzens Reaction to Prepare an Orthogonally Protected Mitomycin C Intermediate with **Maximal Convergency**

Jayasree M. Srinivasan<sup>b</sup>, Priya A. Mathew<sup>a</sup>, Amie L. Williams<sup>b</sup>, John C. Huffman<sup>‡,c</sup>, and Jeffrey N. Johnston<sup>a</sup>

- a Department of Chemistry & Vanderbilt Institute of Chemical Biology Vanderbilt University, Nashville, TN 37235-1822
- <sup>b</sup> Department of Chemistry, Indiana University, Bloomington, IN 47405.
- <sup>c</sup> IU Molecular Structure Center, Indiana University, Bloomington, IN 47405.

#### Abstract

A concise synthesis of a highly functionalized intermediate lacking only C10 of the mitomycin backbone is described. The key to this development is the Brønsted acid-catalyzed aza-Darzens reaction used to forge the cis-aziridine. Additionally an oxidative ketalization fortuitously occurs during the quinone-enamine coupling step, leading to an orthogonally protected hydroquinone.

> The mitomycins are a family of potent antibacterial and anticancer agents that have sustained broad interest since their isolation in the late 1950s due to their biological activity and the synthetic challenge they offer. Mitomycin C (1) has been shown to crosslink DNA and has been clinically used to treat cancer for several decades.<sup>2</sup> The challenge of mitomycin chemical synthesis is largely due to the compact array of reactive functionalities, and reflected by only two total syntheses of rac-mitomycin C and two total syntheses of racmitomycin K.<sup>3,4,5</sup> It could be argued that the length of these preparations (28 steps or more for 1) has limited the further development of the mitomycins as powerful therapeutics.<sup>6</sup>

$$H_2N$$
 $H_2N$ 
 $H_3CO$ 
 $H_3CO$ 

We have outlined a strategy to convergently access the mitomycins using a regioselective enamine-quinone coupling to prepare bromoquinone 2a. The reactivity of this intermediate was reflected by the use of cold column chromatography to purify enamine 2a and its

Correspondence to: Jeffrey N. Johnston.

 $Fax: (+1)\ 615\ 343\ 1234, jeffrey.n.johnston@vanderbilt.edu Homepage: http://www.johnstonchemistry.org.\ ^{\ddagger}To whom questions regarding crystallography should be addressed.$ 

<sup>©</sup> The Royal Society of Chemistry [year]

<sup>†</sup> Electronic Supplementary Information (ESI) available: Complete experimental details and analytical data for all new compounds; Xray data for 12.

tendency to decompose during spectroscopic analysis. As a result of our desire to incorporate new reactions into this sequence to further streamline access to advanced intermediates, we considered the ostensibly less desirable strategy in which both nitrogens bear identical protecting groups (**2b**). In this report, we detail our finding that protecting group differentiation can be achieved during preparation of **2b** by a selective hydride transfer that reduces the quinone, and then protects it via ketalization. Furthermore, the *cis*-aziridine precursor to **2b** is readily prepared using a diastereoselective, Brønsted acid-catalyzed aza-Darzens reaction. <sup>8,9</sup>

Enamine 2a was prepared using a base-promoted aza-Darzens reaction of α-bromo ethyl acetate with the aldimine derived from *tert*-butyl glyoxal. The esters were then chemoselectively refunctionalized to alkyne and aminomethyl substituents of the central *cis*-aziridine. As an alternative, we investigated whether a Brønsted acid-catalyzed aza-Darzens reaction might produce the alkyne-substituted aziridine more immediately. The imine substrate (4) for this was prepared in three steps without purification from commercially available propargyl alcohol (3) (Scheme 1). Alkyne protection of propargyl alcohol was followed by oxidation and condensation of the resulting aldehyde with diphenylmethylamine (DPM-NH<sub>2</sub>) to afford imine 4 (*E:Z*>95:5). The imine *E:Z* ratio is dependent on the alkyne protecting group and ranges from 63:37 (trimethylsilyl) to exclusively *E* geometry (triphenylsilyl group, TPS). The Brønsted acid-catalyzed aza-Darzens reaction of 4 with ethyl diazoacetate provided *cis*-5 in 70% isolated yield compared to 39-50% for the analogous TMS-imine. The ethyl ester was then saponified and coupled with diphenyl methyl amine to give amide 6. Reduction of the amide to amine 7 readied this fragment for coupling.

Cyclization of alkynyl amine **7** with  $HgCl_2$  leads to an intermediate enamine  $^{12}$  (perhaps **8**) that is treated with quinone **9**.  $^{13}$  Standard reductive workup with NaBH<sub>4</sub> was expected to give the hydroquinone of **2b** (**10**, Scheme 2). Although a colorless product was isolated from this mixture, its spectroscopic data was different in key areas from **2a** or its analogous hydroquinone, specifically in the downfield shift of both enamine and pyrrolidine-DPM methine protons by ~0.5 ppm. Assuming the formation of **10**, we treated this material with benzoyl chloride and triethyl amine. A single phenolic hydroxyl group was acylated despite varying reaction conditions. Attempts to oxidatively cleave the pyrrolidine protecting group failed,  $^{14}$  and resulted in oxidation of the hydroquinone and production of benzophenone (a DPM oxidation product).

Since the next planned synthesis step was to install C10, the enamine nucleophilicity was assessed using *N*-chlorosuccinimide. The chlorinated product was crystalline and an X-ray structure was obtained (Figure 1). This revealed that the bromine on the hydroquinone ring had been replaced by a hydrogen and one hydroquinone hydroxyl group had formed a seven-membered ring with the pyrrolidine diphenylmethyl group. By retrospective analysis, the coupling reaction had resulted in an oxidative ketalization to form *N*,*O*-ketal 11, thus explaining the observation that the coupling product could only be singly benzoylated.

This unusual transformation requires two reducing equivalents during the reaction. The oxidation of the pyrrolidine diphenylmethyl group suggested an intramolecular source of one equivalent of hydride. This would also explain why the  $\alpha$ -methylbenzyl-protected pyrrolidine in 2a, which is a poorer hydride donor, did not exhibit this behavior. The second reducing equivalent may be attributed to triethylamine, as variations that did not employ sodium borohydride still produced the mixed ketal.

Our hypothesis that the diphenylmethyl group delivered the hydride was investigated using a deuterium labeling experiment (Scheme 3). Deuterated alkynyl amine *d*-7 was prepared and

subjected to the standard reaction conditions. The coupled *N,O*-ketal showed an 88% deuterium incorporation at the hydroquinone C-H. This verifies that one of the two reducing equivalents results from the conserved transfer of the diphenylmethyl methine. <sup>15</sup>

The mechanism outlined in Scheme 4 for the formation of 11 is consistent with these observations. The initial aminomercuration of alkynyl amine 7 and subsequent enamine addition to quinone 9 would form coupled intermediate 2b. An E/Z isomerization would bring the pyrrolidine in close proximity for the 1,6-hydride shift of the diphenylmethyl methine, resulting in elimination of the bromide and subsequent cyclization of the quinone oxygen onto the iminium ion. A second hydride addition and tautomerization would then give N,O-ketal 11.

The cascade that ensues after coupling of the two halves of the mitomycin backbone was unexpected, but delivers an advanced intermediate containing all but one of the required carbons for mitomycin C. The oxidative ketalization provides differential protection of the hydroquinone hydroxyls while chemically differentiating the pyrrolidine and aziridine nitrogens. Equally important is the maintenance of enamine nucleophilicity, a feature that will be used to install the final carbon. Overall, convergency of approach and the Brønsted acid-catalyzed aza-Darzens reaction of propargyl imine 4 combine to deliver *N*, *O*-ketal 11 in 8 steps.

## **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

Financial support provided by the NIH (GM 063557) is gratefully acknowledged.

## Notes and references

- a Hata T, Sano R, Sugawara A, Matsume K, Shima T, Hoshi T. J. Antibiot. 1956; 9:141. [PubMed: 13385186] b Lefemine DV, Dann M, Barbatschi F, Hausmann WK, Zbinovsky V, Monnikendam P, Adam J, Bohonos N. J. Am. Chem. Soc. 1962; 84:3184.c Webb JS, Cosulich DB, Mowat JH, Patrick JB, Broschard RW, Meyer WE, Williams RP, Wolf CF, Fulmor W, Pidacks C, Lancaster JE. J. Am. Chem. Soc. 1962; 84:3185.d Tulinsky A, van den Hende JH. J. Am. Chem. Soc. 1967; 89:2905. [PubMed: 6043811] e Yahashi R, Matsubara I. J. Antibiot. 1976; 29:104. [PubMed: 931788] f Hornemann U, Heins MJ. J. Org. Chem. 1985; 50:1301.g Shirahata K, Hirayama N. J. Am. Chem. Soc. 1983; 105:7100.
- a Kumar GS, Lipman R, Cummings J, Tomasz M. Biochemistry. 1997; 36:14128. [PubMed: 9369485] b Sartorelli AC. Biochem. Pharmacol. 1986; 35:67. [PubMed: 2416320] c Tomasz M, Lipman R, Chowdary D, Pawlak J, Verdine GL, Nakanishi K. Science. 1987; 235:1204. [PubMed: 3103215] d Szybalski, W.; Iyer, VN. Antibiotics I Mechanism of Action. Gottlieb, D.; Shaw, PD., editors. Springer-Verlag; New York: 1967. p. 211e Kohn H, Zein N, Lin XQ, Ding J-Q, Kadish KM. J. Am. Chem. Soc. 1987; 109:1833.f Andrez J-C. Beilstein J. Org. Chem. 2009; 5:33. [PubMed: 19777135]
- 3. Mitomycin C syntheses: Fukuyama T, Nakatsubo F, Cocuzza AJ, Kishi Y. Tetrahedron Lett. 1977; 49:4295.Fukuyama T, Yang L. J. Am. Chem. Soc. 1987; 109:7881.Fukuyama T, Yang L. J. Am. Chem. Soc. 1989; 111:8303.
- Mitomycin K syntheses: Benbow JW, Schulte GK, Danishefsky SJ. Angew. Chem,. Int. Ed. 1992;
   31:915.Benbow JW, McClure KF, Danishefsky SJ. J. Am. Chem. Soc. 1993; 115:12305.Wang Z,
   Jimenez LS. Tetrahedron Lett. 1996; 37:6049.
- 5. Selected synthetic efforts towards mitomycin C: Ziegler FE, Berlin MY. Tetrahedron Lett. 1998; 39:2455.Coleman RS, Felpin F-X, Chen W. J. Org. Chem. 2004; 69:7309. [PubMed: 15471485]

Shaw KJ, Luly JR, Rapoport H. J. Org. Chem. 1985; 50:4515.Bobeck DR, Warner DL, Vedejs E. J. Org. Chem. 2007; 72:8506. [PubMed: 17910499]

- 6. For reviews of structure-activity comparisons of mitomycin analogues, see: Remers WA. Kingston DGI, Cragg GM, Newman DJ. The Mitomycins. Anticancer Agents from Natural Products. 2005:475.CRC Press LLCBoca Raton, FlaBradner WT, Remers WA, Vyas DM. Anticancer Res. 1989; 9:1095. [PubMed: 2510580] Arai H, Kanda Y, Ashizawa T, Morimoto M, Gomi K, Kono M, Kasai M. J. Med. Chem. 1994; 37:1794. [PubMed: 8021918] Beall HD, Winski SL. Front. Biosci. 2000; 5:D639. [PubMed: 10877993]
- 7. Williams AL, Srinivasan JM, Johnston JN. Org. Lett. 2006; 8:6047. [PubMed: 17165926]
- 8. a Antilla JC, Wulff WD. J. Am. Chem. Soc. 1999; 121:5099.b Antilla JC, Wulff WD. Angew. Chem., Int. Ed. 2000; 39:4518.
- 9. Williams AL, Johnston JN. J. Am. Chem. Soc. 2004; 126:1612. [PubMed: 14871074]
- 10. For a review of reports demonstrating the compatibility of diazoalkanes with Brønsted acids, see: Johnston JN, Muchalski H, Troyer T. Angew. Chem. Int. Ed. 2010; 49:2290.
- 11. Hwu JR, Furth PS. J. Am. Chem. Soc. 1989; 111:8834.
- 12. Aminomercuration lead references: Barluenga J, Aznar F, Liz R, Rodes R. J. Chem. Soc., Perkin Trans. 1. 1980:2732.Barluenga J, Aznar F, Liz R. Synthesis. 1984:304.Barluenga J, Aznar F, Liz R, Cabal M-P. Synthesis. 1986:960.
- 13. Quinone regioselectivity studies lead references: Cox AL, Johnston JN. Org. Lett. 2001; 3:3695. [PubMed: 11700115] Luly JR, Rapoport H. J. Org. Chem. 1981; 46:2745.Stagliano KW, Lu Z, Emadi A, Harwood JS, Harwood CA. J. Org. Chem. 2004; 69:5128. [PubMed: 15255750] Ling T, Poupon E, Rueden EJ, Theodorakis EA. Org. Lett. 2002; 4:819. [PubMed: 11869136] Ling T, Poupon E, Rueden EJ, Kim SH, Theodorakis EA. J. Am. Chem. Soc. 2002; 124:12261. [PubMed: 12371868]
- 14. Luly JR, Rapoport H. J. Am. Chem. Soc. 1983; 105:2859.
- 15. A crossover experiment was not performed to determine whether this transfer is strictly intramolecular

**Scheme 1.**Preparation of an Alkynyl Amine Using the Brønsted Acid-Catalyzed Aza-Darzens Reaction

**Scheme 2.** Formation of an *N,O*-Ketal During the Second Convergent Coupling

**Scheme 3.**Deuterium Labeling Experiment Revealing Selective Transfer of Deuterium from One Diphenylmethyl Group

**Scheme 4.** Mechanistic Proposal for the RedOx Ketalization Subsequent to Coupling

Figure 1. X-ray Crystal Structure of 12